
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics Inc. showcases a promising outlook for its flagship program, FHD-909, which exhibits enhanced SMARCA2 coverage and blockade, suggesting improved patient responses and treatment durability. The potential for the stock to increase by 40-50% in the base case scenario, driven by an overall response rate (ORR) of 10-20% and a duration of response (DoR) ranging from 4-6 months, positions it favorably within the clinical landscape. Additionally, the significant synergy observed when combining FHD-909 with other therapies indicates robust potential for treatment efficacy, particularly in second-line non-small cell lung cancer (NSCLC) settings, further supporting a positive long-term view on the company's financial performance.
Bears say
Foghorn Therapeutics Inc faces significant challenges, as its clinical data has reportedly not met the internal threshold for clinical benefit, potentially affecting its flagship program, FHD-909, and resulting in a necessary pivot due to balance sheet constraints. Additionally, preclinical studies indicate that the candidate molecule exhibits slower degradation kinetics and a hook effect, further raising concerns about its clinical efficacy in treating SMARCA4 mutant NSCLC. The negative outlook is compounded by projections suggesting a downside of 30-40% in stock value amid low response rates and significant treatment-related adverse events, which would yield an unfavorably undifferentiated profile compared to existing therapies.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares